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ORIGINAL ARTICLE
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ABSTRACT
Background: We have reported that BRAF V600E mutations and microsatellite instability-high (MSI-H)
are more prevalent in a population-based cohort of metastatic colorectal cancer (mCRC) patients than
has been reported from clinical trials or hospital-based patient groups. The aim was to explore if other
mutations in mCRC differ in prevalence between these cohorts in relation to mismatch repair status
and primary tumor location and if presence of bone or brain metastases is associated with
any mutations.
Material and methods: A population-based cohort of 798 mCRC patients from three regions in
Scandinavia was used. Forty-four cancer related genes were investigated in a custom designed
Ampliseq hotspot panel. Differences in survival were analyzed using the Kaplan–Meier estimator and
the Cox regression analysis.
Results: Determination of mutations was possible in 449/501 patients for 40/44 genes. Besides BRAF
V600E, seen in 19% of the tumors, none of the other mutations appeared more prevalent than in trial
cohorts. BRAF V600E and MSI-H, seen in 8%, were associated with poor prognosis as was right-sided
primary tumor location (39%) when compared to left-sided and rectum together; however, in a multi-
variable regression, only the BRAF mutation retained its statistical significance. No other mutations
were associated with poor prognosis. ERBB2 alterations were more common if bone metastases were
present at diagnosis (17% vs. 4%, p¼ .011). No association was found for brain metastases. Fifty-two
percent had an alteration that is treatable with an FDA-approved targeted therapy, chiefly by EGFR-
inhibitor for RAS wild-type and a check-point inhibitor for MSI-H tumors.
Conclusions: Right-sided tumor location, BRAF V600E mutations, but no other investigated mutation,
and MSI-H are more commonly seen in an unselected cohort than is reported from clinical patient
cohorts, likely because they indicate poor prognosis. Half of the patients have a tumor that is treatable
with an already FDA-approved targeted drug for mCRC.
Abbreviations: CRC: colorectal cancer; mCRC: metastatic colorectal cancer; MSI-H: microsatellite
instability-high; EGFR: epidermal growth factor receptor; MSI: microsatellite instability; TMA: tissue
microarray; IHC: immunohistochemistry; PCR: polymerase chain reaction; MSS: microsatellite stability;
MSI-L: microsatellite instability-low; SISH: silver-enhanced in situ hybridization; CEP17: INFORM
Chromosome 17; OS: overall survival; VAF: variant allele frequency
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Introduction
Colorectal cancer (CRC) is the third most prevalent cancer
globally [1]. Previous studies have sought to discover prog-
nostic and predictive somatic mutations for novel treatments
in CRC by genomic sequencing [2,3]. This is particularly
important for metastatic CRC (mCRC) patients that have the
poorest survival, median between 10 and 12 months in the
general population and up to 30 months in selected patient
groups [4,5]. It is important that exploratory studies not only
focus on the fittest patients, i.e., those suitable for trial inclu-
sion, but instead look at the entire disease population.
We have shown that BRAF V600E mutations [6] and micro-
satellite instability-high (MSI-H) [7] are more common in an
unselected population of Scandinavian patients with mCRC
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than in patient groups derived from clinical trials or special-
ized hospitals (21% BRAF [6] mutated in the population vs.
5–12% [8–10]; and 7% MSI-H [7] vs. 3–4% [10,11]). A likely
reason for this is that patients with tumors harboring BRAF
mutations or MSI-H have a poor prognosis with short survival
[12,13]; they often fail to be included in trials or are not
referred to specialized hospitals. For decades, the generally
held view was that the primary tumor location was not
important beyond separating colon from rectum. However,
this has recently emerged as a prognostic factor in mCRC
and as a predictive factor for treatment with epidermal
growth factor receptor (EGFR) inhibitors [14]. In a meta-ana-
lysis of 14 first-line studies, the proportion of right-sided
tumors varied between 18 and 36% [15]. Several reports
claim that right-sided tumors have a worse prognosis and
require different treatment upfront, beyond the information
provided by investigation of RAS, BRAF and microsatellite
instability (MSI). However, most of this evidence has been
obtained from trial patients and real-world evidence is lim-
ited [16].
The primary purpose of this study was to explore whether
mutation prevalence, in known cancer genes in an unse-
lected population differs from that reported in trial popula-
tions, and if the location of the primary tumor is prognostic
in a population-based cohort. Further, the unselected mater-
ial allows exploration of mutations related to two uncommon
metastatic sites in mCRC, bone and brain, which are fre-
quently underrepresented in clinical trials. Finally, we wanted
to examine how frequent other molecular changes of poten-




The cohort represents an unselected population of all non-
resectable mCRC patients diagnosed in three regions in
Scandinavia (Uppsala, Sweden; Odense, Denmark; Bergen,
Norway), with an mCRC diagnosis between October 2003
and August 2006 [17]. An informed consent was signed by
all patients expect for 49 patients identified from regional
cancer registries [6]. All information was prospectively col-
lected from the clinical records by clinicians and research
nurses, subsequently anonymized and de-identified before
analysis. Regional ethical committees in Norway, Sweden and
Denmark approved the study as well permission to include
patients not prospectively identified to make the cohort truly
population-based.
Tissue retrieval, tissue microarray generation and
DNA extraction
Hematoxylin–eosin stained slides from primary tumors or
metastases were examined so representative tumor parts
could be selected from the corresponding tissue blocks, and
non-necrotic tumor areas with few other cells admixed
marked. Tissue microarray (TMA) generation and DNA
extraction were performed using 1mm tissue cores from the
original primary tumor block except in six patients that were
from metastatic lesions. The Beecher Instruments Manual
Tissue Arrayer MTA-1 was used to generate TMAs. DNA was
recovered from 505 (63%) tissue cores by Recoverall Total
Nucleic Acid Isolation kit (Ambion, Austin, TX, USA). The
remaining cases had either no remaining cancer tissue or
not enough material to take cores for research; these were
all diagnosed using small colorectal biopsies or needle biop-
sies of metastatic lesions.
Microsatellite instability analysis
MSI status was determined via a combination of immunohis-
tochemistry (IHC) and polymerase chain reaction (PCR) tech-
niques, see Supplementary Methods.
ERBB2/HER2 IHC and dual-color silver-enhanced in situ
hybridization (SISH)
Tumors were stained with a monoclonal antibody against
human HER2, clone CL0268 (mouse), dilution 1:250 (Atlas
Antibodies, Stockholm, Sweden). Protein expression was
ranked from 1þ (weak intensity) to 3þ (strong intensity).
Bright-field dual-color SISH analysis was performed for all
TMAs using an automatic SISH staining device BenchMark
ULTRA, according to manufacturer’s instructions for INFORM
HER2 DNA and INFORM Chromosome 17 (CEP17) probes
(Ventana Medical Systems, Tucson, AZ, USA). HER2/CEP17
SISH signals were counted for all 2þ and 3þ IHC scored
samples according to the guidelines for staining of gastric
cancers. All samples with a HER2/CEP17 ratio 2.0 were con-
sidered to have amplified ERBB2 expression. Adjacent benign
cells were used as controls. HER2 status was also determined
accordingly to HERACLES diagnostic criteria for CRC [18].
Targeted sequencing and data analysis
A custom designed Ampliseq hotspot panel (Thermo-Fisher
Scientific, Waltham, MA, USA) covering 194 amplicons from
44 cancer related genes was designed using Ion AmpliSeq
Designer (Supplementary Table 1). The AmpliSeq panel was
designed using specific settings customized for FFPE sam-
ples. Sequencing libraries were prepared from 10 ng of gen-
omic DNA according to the Ion AmpliSeq Library Kit 2.0 user
guide and quantified using the Agilent Bioanalyzer instru-
ment and the Agilent High Sensitivity DNA kit. Emulsion PCR,
enrichment and chip loading were performed on the Ion
Chef system using the Ion PI Chef Kit (Thermo Fisher
Scientific, Waltham, MA, USA). The samples were sequenced
on the Ion Proton System using an Ion PI chip and
200 bp chemistry. Data analysis and variant calling were per-
formed as described in Supplementary Methods. Somatic
alterations were defined in tiers according to OncoKB
levels of evidence [19] and presented in a figure made with
Oncoprinter [20,21].
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Statistical analyses
Fisher’s exact test was performed for group comparisons and
p value< .05 was considered statistically significant. Overall
survival (OS) was the time between the dates of diagnosis of
metastatic disease and death or censored for patients alive
in February 2014. The Kaplan–Meier estimator and the Cox
multiple regression were used for OS analysis. Statistical anal-
yses were performed using R software, version 3.6.0 (R
Foundation for Statistical Computing, Vienna, Austria).
Results
Cohort and mutation characterization
The study included 798 patients, of which 701 patients had
surgical specimens with invasive cancer. Tissue cores could
be generated from 505 patients (Supplementary Figure 1).
The sequenced patients were representative of the entire
cohort, by age and sex distribution, and primary tumor loca-
tion (Supplementary Table 2). Sequencing data were
obtained from 501 tumors at a median amplicon coverage
per tumor of 4,801. EZH2 had the highest amplicon coverage
(median 19,084) while PTEN had the lowest coverage
(median 2,194) (Supplementary Table 3). Due to the high
overall coverage, we used a stringent cutoff of 1,000-fold
average coverage; 95% (476/501) of the samples met this cri-
terion. After applying the filters described in Supplementary
Methods, 411/449 (92%) patients carried at least one muta-
tion in 40/44 genes sequenced (EZH2, HNF1A, MPL and SRC
had no mutations). In total, 1,249 somatic nonsynonymous
single-nucleotide variants and indels were identified (40
frameshift deletions, 33 frameshift insertions, four non-frame-
shift deletions, 984 missense and 188 nonsense point muta-
tions), corresponding to 437 unique and 142 recurrent
mutations within the set. The most recurrent hotspot muta-
tion was BRAF V600E (86 cases) followed by KRAS G12D and
G12V with 60 and 40 cases, respectively. From the gene
panel, 6/44 genes were mutated in more than 10% of the
patients, namely TP53 (242/449; 54%), KRAS (201/449; 45%),
APC (155/449; 35%), BRAF (93/449; 21%), PIK3CA (84/449;
19%) and SMAD4 (56/449; 12%) (Figure 1). To identify signifi-
cantly mutated genes, we fit a linear regression model using
the total number of sequenced base pairs and total number
of mutations for each gene. Ten genes, KRAS, BRAF, TP53,
APC, CTNNB1, PIK3CA, AKT1, NRAS, SMAD4 and FBXW7 had a
higher mutation rate than expected by chance
(Supplementary Figure 2).
Microsatellite instability
By combining the data from IHC and PCR genotyping, we
divided the cohort in MSI-H (36/449; 8%) and MSS/MSI-L
phenotypes (413/449; 92%), referred to as MSS. As expected,
MSI-H patients were predominately females with poorly or
undifferentiated tumors located in the right colon (Table 1)
[11]. They differed in metastatic pattern from MSS tumors
with fewer liver (36% vs. 66%, p< .001) and lung (6% vs.
26%, p¼ .004) metastases but more lymph node metastases
(53% vs. 28%, p¼ .004). Overall, 64% of the patients received
chemotherapy with no significant difference between MSI-H
and MSS tumors. OS was shorter in patients with MSI-H
tumors (6 vs. 13 months, p¼ .006), even when only consider-
ing patients receiving chemotherapy (11 vs. 19 months,
p¼ .013, Figure 2(A,B)). Complete or partial response to first-
line treatment was higher for the MSS cases (43% vs. 5%,
p< .001, Table 1). As expected, the MSI-H patients had a
higher BRAF mutation prevalence (75% vs. 16%, p< .001,
Supplementary Table 4) and OS was shorter if the tumor was
BRAF mutated (Figure 2(C,D)). From the significantly mutated
genes, only APC (37% vs. 11%, p¼ .002) and KRAS (48% vs.
11%, p< .001) had significantly higher mutation prevalence
in MSS compared to MSI-H tumors (Supplementary Table 4).
Aside from BRAF, no other significantly mutated gene was
associated with poor prognosis even when considering first-
line treated patients only (Supplementary Figure 3).
Gene alterations according to primary tumor location,
age and selected metastatic sites
In the cohort of 449 patients with sequenced tumors, 38%
were right-sided (right colon and transversum), 35% left-
sided (left colon and sigmoideum) and 25% were rectal
tumors. The patients with right-sided tumors were more
likely to be older, female and have poorly differentiated
tumors with lymph node and peritoneal metastases
(Table 2). The MSI-H phenotype was more frequent in right-
sided tumors (18% vs. 1% and 3% for left-sided and rectal
tumors, respectively, p< .001). Similarly, BRAF mutation fre-
quency was higher in right-sided tumors but decreased
throughout the left colon and rectum (38% vs. 14% vs. 5%,
p< .001). Also, the PIK3CA mutation frequency was highest in
the right colon, followed by rectal tumors and lowest in the
left colon (24% vs. 17% vs. 13%, p¼ .044). No other gene
mutation prevalence differed significantly by primary tumor
location. No gene mutation prevalence, aside from AKT1, was
influenced by age (Supplementary Table 5). In all patients
(and in patients treated with chemotherapy, for choice of
chemotherapy, see Supplementary Figure 4), no significant
differences could be detected for OS according to tumor
sidedness based on MSI expression and BRAF mutation status
(Figure 2(E,F); Table 2). When right-sided colon tumors were
compared with left-sided colon and rectum tumors together,
median OS was 10 months vs. 14 months for all patients
(p¼ .046) and 15 months vs. 18.5 months (p¼ .270) for
patients that received first-line treatment. In a multiple Cox
regression analysis, including MSI status, BRAF mutation sta-
tus, primary tumor location (right colon vs. left colon and
rectum together) and whether the patient received first-line
treatment, only BRAF mutation was significantly associated
with reduced OS, while receiving first-line treatment was
associated with an increased OS (Supplementary Figure 5).
Patients with bone metastases at time of diagnosis of
metastatic disease (n¼ 30, 7%) more often had a rectal pri-
mary (54%) than a colon primary (29% right-sided and 18%
left-sided, p¼ .004), and more often lung (p¼ .049) and mul-
tiple site metastases (p< .001), but less often liver metastases
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(p¼ .009). They also received radiotherapy more often than
patients without simultaneous bone metastases (57% vs. 7%,
p< .001). Patients with bone metastases had poorer perform-
ance status and their OS was significantly shorter (8 vs.
12 months, p¼ .015). None of the patients with simultaneous
bone metastases had MSI-H tumors, but two (6%) patients
with MSI-H tumors later developed bone metastases. Thirty-
nine (10%) patients with MSS tumors without simultaneous
bone metastases later developed bone metastases.
Furthermore, ERBB2 alteration was more often seen in
patients with simultaneous bone metastasis (17% vs. 4%,
p¼ .011, Supplementary Table 6).
No patient had brain metastases at the time of diagnosis
of their primary tumor. Of the 26 patients who developed
brain metastases after a median of 20 months (range 1–139),
one (3%) developed in a patient with an MSI-H tumor and
25 (6%, p¼ .711) in patients with MSS tumors. Lung metasta-
ses were more common for the patients with brain metasta-
ses (54% vs. 23%, p¼ .001) and no gene alteration frequency
differed between these groups (Supplementary Table 7).
Clinically actionable alterations
KRAS was the most altered oncogene with 45% of the
tumors having at least one oncogenic alteration. Five MSS
patients had two co-occurring KRAS mutations, where one of
them had two known oncogenic mutations (G13D and A18T
with variant allele frequency (VAF) of 12%, Supplementary
Figure 6A). NRAS was altered in 4.5% of the cases. BRAF was
Figure 1. Frequency of altered genes in a Scandinavian unselected cohort of metastatic colorectal cancer by type of mutation.
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mutated in 21% of the cohort and the most common BRAF
alteration was V600E, observed in 19% of tumors. One MSS
patient had a complex substitution (c.1798_1799GT>AG) in
BRAF that led to a rare V600R alteration. Non-V600 BRAF
mutations were present in six cases and further classified
according to [22]; G469R, a class 2 mutation leading to inter-
mediate kinase activity; G466E (two cases), D594G and
D594N, class 3 alterations leading to no kinase activity; and
V590I of undefined non-V600 class described in one previous
salivary gland tumor [23]. Two of the class 3 alterations,
observed in colon cancers were co-mutated with KRAS, while
two were present in rectal cancers without KRAS co-
mutation. Two patients had two co-occurring BRAF muta-
tions, where one of them presented two neighboring onco-
genic mutations (V600E and K601N with VAF of 33% and
26%, respectively, Supplementary Figure 6B). PIK3CA was
altered in 84 (19%) patients. In total, 15 (3.3%) patients were
scored 2þ or 3þ by IHC and had a positive SISH analysis for
ERBB2 according to the breast and gastric cancer criteria,
while 12 (2.6%) had this when considering HERACLES CRC
diagnostic criteria. One-third of the patients had a co-occur-
ring KRAS mutation irrespective of what criteria was used
(Supplementary Table 8). ERBB2 mutation was found in seven
additional cases.
Table 1. Comparison of patient and tumor characteristics between patients with MSS and MSI-H tumors.
Characteristics
MSS patients (n¼ 413)
n (%)
MSI-H patients (n¼ 36)
n (%) p Value Missing
Age (years)
Meanþ S.D. 68.4þ 12.3 71.0þ 14.0
Median (range) 68 (24–96) 74.5 (22–85)
>75 years 132 (32) 17 (47) ns (.067)
Sex
Male 214 (52) 11 (31) .015
Female 199 (48) 25 (69)
Primary tumor location
Right colon 141 (34) 30 (83) <.001
Left colon 155 (38) 2 (6)
Rectum 111 (27) 3 (8)
Multiplea 6 (1) 1 (3)
Synchronous metastases 213 (52) 24 (67) ns (.116)
Tumor grade
Grade 1–2: well-medium differentiated 295 (82) 12 (36) <.001 55
Grade 3–4: poorly-undifferentiated 66 (18) 21 (64)
Primary tumor resected 377 (91) 33 (92) ns (1.000)
Metastasesb
Liver 273 (66) 13 (36) <.001
Lymph node 115 (28) 19 (53) .004
Lung 108 (26) 2 (6) .004
Peritoneum 78 (19) 6 (17) ns (1.000)
Abdominal mass 31 (8) 2 (6) ns (1.000)
Bone 30 (7) 0 (0) ns (.156)
Skin 8 (2) 1 (3) ns (.532)
Local relapse 24 (6) 5 (14) ns (.072)
Other soft tissue 12 (3) 2 (6) ns (.311)
Performance status
0–1 283 (69) 21 (58) ns (.264) 1
2–4 129 (31) 15 (42)
Weight loss >5% 155 (41) 21 (62) .019 33
Best supportive care 120 (29) 14 (39) ns (.255) 1
1st-line chemotherapy 269 (65) 19 (53) ns (.150)
5-FU monotherapy 50 (12) 6 (17) ns (.429)
Combination chemotherapyc 211 (51) 13 (36) ns (.117)
2nd-line chemotherapy 159 (39) 7 (19) .030 1
3rd-line chemotherapyd 76 (18) 1 (3) .011 2
1st-line response rate
CR/PR 103 (43) 1 (5) <.001 193
SD 94 (40) 10 (53)
PD 40 (17) 8 (42)
Development of brain metastases 25 (6) 1 (3) ns (.711) 1
Development of bone metastasese 59 (14) 2 (6) ns (.204) 2
Last status
Alive 18 (4) 1 (3) ns (1.000)
Dead 395 (96) 35 (97)
Median overall survival (95% CI) all patients 13 m (11.3–14.7) 6 m (3.1–8.9) .006
Received 1st-line treatment 19 m (16.3–21.7) 11 m (6.8–15.2) .013
aMultiple: rectum and colon locations.
bMetastases: at time of diagnosis of metastatic disease.
cCombination chemotherapy: irinotecan or oxaliplatin with a fluoropyrimidine (FU).
dPatients that received 3rd-line chemotherapy or more (until 5th-line).
e30/59 patients had bone metastasis already at diagnosis of metastatic disease.
ns: not significant; S.D.: standard deviation; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; p value:





Figure 2. The Kaplan–Meier analysis of overall survival (OS) for all patients and for patients given 1st-line chemotherapy treatment according to MSI status, BRAF
mutation and primary tumor location. p value was calculated with log-rank test. (A) OS for all patients and (B) for patients given 1st-line chemotherapy by MSI sta-
tus. (C) OS for all patients and (D) for patients given 1st-line chemotherapy by BRAF mutation status. (E) OS for all patients and (F) for patients given 1st-line
chemotherapy by primary tumor location.
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Discussion
Numerous studies have explored the genomic and phenotyp-
ical heterogeneity in mCRC, but almost exclusively from
selected trial or hospital-based patient series not representa-
tive of the general population. We evaluated genomic prop-
erties in almost 450 mCRC tumors from an unselected
population-based cohort where all diagnosed individuals
with mCRC not immediately possible to resect were identi-
fied. We could substantiate that BRAF V600E mutations and
MSI-H are about twice as common as in previously reported
datasets. While other studies commonly report about 6–8%
(range 5–12%) BRAF V600E mutations [24] and 3–4% MSI-H
tumors [11], this study revealed 19% BRAF V600E mutations
and 8% MSI-H. The likely explanation for this is the poor
prognosis of these patient groups; therefore, they are under-
represented in patient materials from clinical trials or hos-
pital-based cohorts where patients must fulfill certain
inclusion. The lower than expected mutation frequency in
two genes, APC and TP53, 35% vs. expected 80% and 54%
vs. expected 65%, respectively can likely be explained by
incomplete coverage of these genes in the gene panel
design where only the main mutation driver cluster regions
were covered as previously published by Overman et al. [25].
None of the other known somatic mutations of potential
interest in mCRC, including PIK3CA mutations and ERBB2
expression, were more prevalent in this patient group com-
pared to other cohorts, indicating that the prognosis for
those groups is not particularly poor. Since both BRAF V600E
mutation and MSI-H phenotype are indicators of poor
Table 2. Comparison of patient characteristics and altered genes by primary tumor location (seven patients had multiple sites).
Characteristics
Right colon (n¼ 171)
n (%)
Left colon (n¼ 157)
n (%)
Rectum (n¼ 114)
n (%) p Value
Age (years)
Meanþ S.D. 71.9þ 10.2 65.9þ 13.2 67.1þ 12.9
Median (range) 73 (47–96) 65 (24–92) 68 (22–93)
>75 years 70 (41) 39 (25) 37 (32) .008
Sex
Female 100 (58) 78 (50) 42 (37) .002
MSI status
MSS 141 (82) 155 (99) 111 (97) <.001
MSI-H 30 (18) 2 (1) 3 (3)
Synchronous metastases 93 (54) 100 (64) 40 (35) <.001
Tumor gradea
Grade 1–2: well-medium differentiated 104 (66) 117 (84) 81 (89) <.001
Grade 3–4: poorly undifferentiated 53 (34) 23 (16) 10 (11)
Metastasesb
Liver 99 (58) 118 (75) 63 (55) <.001
Lymph node 63 (37) 44 (28) 26 (23) .033
Lung 31 (18) 43 (27) 35 (31) .031
Peritoneum 46 (27) 23 (15) 12 (11) .001
Abdominal mass 15 (9) 12 (8) 5 (4) ns (.363)
Bone 8 (5) 5 (3) 15 (13) .004
Skin 6 (4) 1 (1) 2 (2) ns (.242)
Local relapse 7 (4) 7 (4) 15 (13) .008
1st-line treatment 102 (60) 107 (68) 75 (66) ns (.259)
Combination chemotherapyc 70 (41) 90 (57) 61 (54) .008
Median overall survival (95% CI) all patientsd 10 m (7.6–12.4) 14 m (11.5–16.5) 11 m (8.2–13.8) ns (.058)
Received 1st-line treatmente 15 m (10.8–19.2) 21 m (17.3–24.7) 18 m (11.4–24.6) ns (.303)
MSI-H 4 m (1.0–7.2) 2 m 9 m (0–23.4) ns (.609)
MSS 10 m (7.5–12.5) 15 m (12.8–17.1) 12 m (9.1–14.9) ns (.163)
BRAF mutated 6 m (2.6–9.4) 14 m (8.4–19.7) 2 m (1–3.1) ns (.122)
Mutations (significantly mutated genes)
KRAS 76 (44) 67 (43) 27 (47) ns (.818)
BRAF 65 (38) 22 (14) 6 (5) <.001
TP53 93 (54) 83 (53) 62 (54) ns (.962)
APC 57 (33) 50 (32) 45 (40) ns (.395)
CTNNB1 3 (2) 4 (3) 3 (3) ns (.850)
PIK3CA 41 (24) 21 (13) 19 (17) .044
AKT1 8 (5) 7 (5) 2 (2) ns (.443)
NRAS 4 (2) 10 (6) 6 (5) ns (.171)
SMAD4 22 (13) 18 (12) 14 (12) ns (.932)
FBXW7 12 (7) 8 (5) 11 (10) ns (.350)
ERBB2 alterations
Mutation 1 (1) 1 (1) 5 (4) .030
Mutationþ amplification 7 (4) 5 (3) 10 (9) ns (.106)
BRAF non-V600 mutationsf 2 (1) 1 (1) 2 (2) ns (.852)
aMissing for 54 patients.
bMetastases: at time of diagnosis of metastatic disease.
cCombination chemotherapy: irinotecan or oxaliplatin with a fluoropyrimidine.
dIf right-sided colon cancers were compared with left-sided colon and rectum together, median survival was 10 months (7–12) vs. 14 months (12–16), p¼ .046.
eIf right-sided colon cancers were compared with left-sided colon and rectum together, median survival was 15 months (13–20) vs. 18.5 months
(16–23), p¼ .270.
fBRAF non-V600 mutations with defined classification.
ns: not significant; S.D.: standard deviation; p value: Fisher’s exact test for dichotomous and nominal variables and the log-rank test for survival times.
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prognosis and poor response to conventional chemotherapy,
there is an urgent need to determine these properties at the
time of diagnosis. The very poor prognosis for patients with
MSI-H tumors is likely a combination of a more aggressive
tumor and a poorer response to therapy. The very poor
response to first-line treatment in patients with MSI-H tumors
reported here, underlines the importance of evaluating
immunotherapy upfront [26].
In contrast to most recent studies in mCRC, this study
could not substantiate worse survival for right-sided com-
pared to left-sided tumors [27,28]. In this study and a
Canadian population study [16], we find that about 40% of
patients with mCRC have a right-sided tumor. The two mCRC
subgroups with the worst prognosis, MSI-H and BRAF-
mutated tumors are all more common in right-sided tumors.
Whether the poor prognosis of right-sided tumors is solely
caused by these molecular properties is still an unresolved
question, but it has been suggested that even if there is no
overactivation of the MAPK signaling pathway, right-sided
tumors should not be treated with EGFR-inhibitors [14]. The
Canadian study also noticed poorer prognosis for treated
patients (47% received chemotherapy) with right-sided
tumors but did not report any molecular analyses.
Interestingly, in this cohort, BRAF and PIK3CA were the only
genes with significantly higher mutation prevalence in right-
sided tumors, as previously reported [27,29]. However, we
did not observe that any other gene was associated with
sidedness, which could be due to the unselected nature of
this cohort.
Wild-type KRAS and NRAS are FDA-approved biomarkers
for administration of anti-EGFR antibodies [30–32], and 51%
(230/449) of the cases in this study were wild-type for both
genes. Further, BRAF and PIK3CA mutations or ERBB2 amplifi-
cations can also result in resistance to EGFR-inhibition [33]
meaning that only about half (126/230) of the RAS wild-type
patients are ideal candidates for this treatment. ERK and MEK
inhibitors are studied as targeted drugs for RAS oncogenic
mutations [34], as well as AMG 510 (NCT03600883), a novel
small molecule KRAS G12C inhibitor potentially suitable for
2% (8/449) of our cohort. In mCRC, there is compelling clin-
ical evidence for the use of encorafenib and cetuximab with
binimetinib in patients with BRAF V600E mutation, meaning
this could be a possible therapy for 19% (87/449) of this
cohort [35]. In vitro evidence supports the use of PLX8394
for BRAF non-V600 alterations [36], present in five (1%)
patients in this study. ERBB2 amplification assessment is rou-
tinely done in breast and esophagogastric cancers as these
tumors can be targeted by FDA-approved drugs. We could
detect ERBB2 amplification with SISH analysis in 3% (15/449)
of the patients, translating to the percentage of mCRC
patients that could benefit from targeted therapy. Increasing
evidence has led to FDA approval of the use of immune
checkpoint inhibitors in patients with MSI-H tumors, repre-
senting 8% (36/449) of our population [37]. To summarize,
53% (237/449) of our cohort could have potential benefit
from an FDA-approved targeted therapy in mCRC, mainly
based on the absence of overactive RAS-MAPK signaling
(Figure 3).
Figure 3. Distribution of patients with an FDA-approved (237/449, 53%) or
potentially actionable alteration in an unselected cohort of metastatic colorectal
cancers. Total amount of mutations, OncoKB levels of evidence, MSI status and
mutation status of selected genes are represented in different columns for all
patients. Each row represents one patient. Color coding indicates the type of
event in each column. Patients in rows indicated with level 1 evidence have at
least one FDA-approved biomarker that responds to an FDA-approved drug
(RAS wild-type, EGFR-inhibitor; MSI-H, checkpoint inhibitor); patients in level 2A
have at least one standard of care biomarker predicted to respond to an FDA-
approved drug (BRAF V600E, BRAF-inhibitor); those in level 4 have a biomarker
with predictive compelling biological evidence to respond to a drug (KRAS
mutation, MEK-inhibitor) and level those in R1 have a standard care biomarker
that is resistant to an FDA-approved drug (NRAS mutation, EGFR-inhibitor).
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In conclusion, aside from MSI-H phenotype and BRAF
V600E mutations, no other molecular change was more, or
less, prevalent than in selected cohorts. Both MSI-H and
BRAF mutation are associated with poor prognosis, poten-
tially explaining why these features are more prevalent than
has previously been reported [8–11]. This may also explain
why there is no difference in mutation prevalence for other
genes included in this study, as no other mutation was asso-
ciated with poor prognosis. However, the limited numbers
for most of those mutations prevent us from making firm
conclusions. Besides alterations in ERBB2, seen more fre-
quently if bone metastases were present, we could not iden-
tify alterations associated with the rarer metastatic sites of
bone or brain. Similar to previous studies, a rectal primary
was more often associated with bone metastatic sites than
colon cancer [38]. Finally, and opposed to a generally held
view [27,28], we could not substantiate that right-sided
tumors that do not harbor a BRAF mutation or an MSI-H
phenotype have a worse outcome than left-sided tumors,
whether receiving chemotherapy or not.
The patient material collected from 2003 to 2006 and the
comparatively short OS could make one question the rele-
vance of using this study to draw conclusions that are
applicable to today’s mCRC diagnosis and prognosis.
However, the tumor panorama has not changed, and the OS
reflects the population-based nature of the material. As such,
it is likely unique. The median OS of 9 months (7.8–10.2) is
heavily influenced by the non-actively treated patients (43%
of all patients), due to their old age, presence of severe co-
morbidities or very aggressive disease with poor perform-
ance status. The comparatively low median OS of 15 months
(13.4–16.6) in the chemotherapy group can be explained by
(i) the 22% that only received single fluoropyrimidine, (ii) the
inclusion of patients with co-morbidities and laboratory
abnormalities that disqualify them from trial participation
and (iii) the exclusion of patients with upfront resectable
metastatic disease. For patients eligible for trial participation,
all three active cytotoxic drugs, bevacizumab and the EGFR-
inhibitor cetuximab were available and used, resulting in a
median OS of about 24 months [17], in line with what has
been reported from clinical trials including mCRC patients
[30,31,39]. The up to 30 months median OS reported in
recent trials [4] reflects molecular selection and the inclusion
of patients having resectable metastatic disease. Thus, we
believe our prognostic associations are relevant for today’s
patients. Taken together, we present unbiased mutation fre-
quencies in mCRC and estimate the true percentage of
patients potentially eligible for targeted treatment in an
unselected western-world mCRC cohort.
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